The company has since kicked off equine trials to see if the same technology can predict muscle damage in top-tier racehorses.
OxiDx is just one of several cutting-edge blood tests Proteomics has in the pipeline as it zeros in on some of the world’s most lucrative and urgent health markets.
The company also recently rolled out its first commercial product called “PromarkerD” in Australia and the US. That breakthrough diagnostic test delivers an early warning for chronic kidney disease in people with type 2 diabetes. Clinical trials show PromarkerD can flag the condition up to four years before symptoms appear, giving doctors and patients a critical head start on treatment.
With over 500 million people living with diabetes globally, Proteomics says there is a massive upside opportunity for PromarkerD and it is gunning to make it the gold standard in kidney disease prevention.
With the IP armoury now locked and loaded across key global markets, Proteomics appears a step closer to unlocking lucrative new revenue streams.
Its OxiDx technology could be a game-changer for health, performance and injury management in elite athletes, champion racehorses or indeed, anyone just trying to stay ahead of the health curve.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
- For more: Elrisala website and for social networking, you can follow us on Facebook
- Source of information and images “brisbanetimes”“
